Johnson & Johnson: Colitis, Ulcerative trials

The registry lists 44 Colitis, Ulcerative studies with Johnson & Johnson as lead sponsor. 13 are open to participants now and 12 have results posted.

Phase 1 3Phase 2 8Phase 3 18Phase 4 2No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian SettingNot yet recruitingNCT07851207
• A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative ColitisNot yet recruitingNCT07848737
• A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNot yet recruitingNCT07746765
• A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyRecruitingNCT07654751Phase 4
• A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative ColitisRecruitingNCT07606339
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07577856Phase 3
• A Study to Assess Real-world Outcomes for Long-Term Use of GuselkumabRecruitingNCT07532213
• A Real-World Study of Guselkumab in Chinese Participants With Ulcerative ColitisRecruitingNCT07302360
• A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)RecruitingNCT07242248
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07196748Phase 3
• A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in GermanyRecruitingNCT07102368
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingNCT06663332Phase 3
• A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative ColitisRecruitingNCT04372108
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT05528510Phase 3Results posted
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)CompletedNCT04630028Phase 3Results posted
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT04033445Phase 2/3Results posted
• A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03662542Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT03596645Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT02407236Phase 3Results posted
• A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.CompletedNCT01863771Phase 3Results posted
• A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)CompletedNCT01804166Phase 4Results posted
• An Efficacy and Safety Study of Golimumab in Participants With Ulcerative ColitisTerminatedNCT00488774Phase 2/3Results posted
• An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT00488631Phase 3Results posted
• An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT00487539Phase 2/3Results posted
• A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative ColitisCompletedNCT00336492Phase 3Results posted
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06260163Phase 3
• A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT06049017Phase 2
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT05242484Phase 2
• A Long-term Extension Study of Ustekinumab in Pediatric ParticipantsActive, not recruitingNCT05092269Phase 3
• A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical PracticeCompletedNCT04963725
• A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative ColitisTerminatedNCT04457960Phase 1
• Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory DiseasesCompletedNCT03606499
• A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative ColitisTerminatedNCT03358706Phase 1
• Tracking Biologics Along the Silk RoadCompletedNCT03006198
• An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisActive, not recruitingNCT02808780
• Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in KoreaCompletedNCT02229344
• A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT01988961Phase 2
• A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT01959282Phase 2
• A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative ColitisCompletedNCT01900574Phase 1
• A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative ColitisCompletedNCT01551290Phase 3
• A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel DiseaseActive, not recruitingNCT00606346
• A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis PatientsCompletedNCT00207688
• A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative ColitisCompletedNCT00096655Phase 3
• A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative ColitisCompletedNCT00036439Phase 3